BEIJING and SHANGHAI and BOSTON, Oct. 23, 2025 /PRNewswire/ — Jacobio Pharma (1167.HK) announced that it presented the pre-clinical data of its internally discovered pan-KRAS inhibitor JAB-23E73 in a poster presentation at the 2025 AACR-NCI-EORTC […]
BEIJING and SHANGHAI and BOSTON, Oct. 23, 2025 /PRNewswire/ — Jacobio Pharma (1167.HK) announced that it presented the pre-clinical data of its internally discovered pan-KRAS inhibitor JAB-23E73 in a poster presentation at the 2025 AACR-NCI-EORTC […]
BEIJING, SHANGHAI and BOSTON, Sept. 25, 2025 /PRNewswire/ — Jacobio Pharmaceuticals (1167.HK) today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the […]
BEIJING, SHANGHAI and BOSTON, Sept. 25, 2025 /PRNewswire/ — Jacobio Pharmaceuticals (1167.HK) today announced that its Chairman and Chief Executive Officer, Dr. Yinxiang Wang, together with concerted parties, have recently increased their shareholding in the […]
BEIJING and SHANGHAI and BOSTON, Aug. 30, 2024 /PRNewswire/ — Jacobio Pharma (1167.HK), a clinical-stage oncology company focusing on undruggable targets, today announced that it has granted the China rights (including mainland China, Hong Kong, Macau, […]
